This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;284:33.

	Since this article does not have an abstract, we have provided the first 100 words of the full text and any section headings.

The FDA's Nonprescription Drugs and Endocrinologic and Metabolic Drugs committees will hold a joint meeting to consider applications for over-the-counter use of cholesterol-lowering agents. On July 13, the subject will be Mevacor (lovastatin, 10-mg tablets), and on July 14, Pravachol (pravastatin sodium, 10-mg tablets). The meeting will be at the Holiday Inn, 8120 Wisconsin Ave, Bethesda, Md. Interested persons may make oral presentations from 8 AM to 9 AM on July 13. Written submissions may be made to Sandra Titus or Kathleen Reedy, HFD-21, FDA, 5600 Fishers Lane, Rockville, MD 20857.

AUTHOR INFORMATION

Written inquiries may be directed to Jane E. Henney, MD, Commissioner of Food and Drugs, HF-1, Room 14-71, 5600 Fishers Ln, Rockville, MD 20857.

Jane E. Henney, MD
Commissioner of Food and Drugs

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?